Results 111 to 120 of about 2,223,573 (201)

Gefitinib-Related Interstitial Lung Disease in Taiwanese Patients With Non-Small-Cell Lung Cancer

, 2014
Gefitinib is effective in the treatment of non-small-cell lung cancer (NSCLC), especially in the Asian population. However, interstitial lung disease (ILD) is usually a serious pulmonary adverse effect.
Chang, Shih-Chieh;Chang, Cheng-Yu;Chang, Shu-Ju;Yuan, Mei-Kang;Lai, Yi-Chun;Liu, Yu-Chang;Chen, Cheng-Yu;Kuo, Li-Chiao;Yu, Chong-Jen, 余忠仁   +1 more
core  

Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer

Oncotarget, 2015
Here, we showed the antibiotic salinomycin (SAL) combined with GEF exerted synergistic cytotoxicity effects in colorectal cancer cells irrespective of their EGFR and KRAS status, with a relatively low toxicity to normal cells. Additionally, combination of the two drugs overcame Ras-induced resistance and the acquired resistance to GEF.
Zou, Zheng-Zhi, Nie, Pei-Pei, Li, Ya-Wei, Hou, Ben-Xin, Rui-Li,, Shi, Xin-Peng, Ma, Zhao-Kui, Han, Bao-Wei, Luo, Xiao-Yong   +8 more
openaire   +3 more sources

A cross-talk between integrin β4 and epidermal growth factor receptor induces gefitinib chemoresistance to gastric cancer

Cancer Cell International, 2018
Background Gastric cancer presents a major health burden worldwide. Therefore, many molecular targeting agents have been evaluated for treatment of gastric cancer.
Jia Huafeng, Zhang Deqing, Ding Yong, Zhang Yulian, Hu Ailing   +4 more
doaj   +1 more source

Pan‐Cancer Analysis of the Immunomodulatory Roles and Prognostic Value of PDXP and Experimental Verification in SKCM

Cancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Multiple public databases, including TCGA, GEO, and TARGET, were utilized to comprehensively analyze pyridoxal phosphatase (PDXP) expression profiles across 34 cancer types. We further explored the associations of PDXP expression with clinicopathological features, tumor immune microenvironment, genomic heterogeneity, functional signaling ...
Yingjian Hu, Xinzhu Zeng, Wei Cao, Jianhao Jiao, Yuan Zhao, Jun Wang   +5 more
wiley   +1 more source

Variant‐Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs

International Journal of Cancer, Volume 159, Issue 7, Page 1715-1734, 1 October 2026.
Mutual exclusivity and co‐occurrence of oncogenic mutations reflect functional antagonism or dependence and may inform therapeutic strategies. However, most studies overlook variant‐level patterns. In this comprehensive, cross‐cohort analysis of BRAF, KRAS, and EGFR mutation subtypes, the most significant mutual exclusivity pairs overlapped with ...
Freya Vaeyens, Jan‐Patrick Hetzel, Khaldoon Abdullah, Carolien Eggermont, Catharina Olsen, Marco Mernberger, Ken Maes, Jelle Vlaeminck, Rainer Claus, Dries Vanisterbecq, Frederik Hes, Martin Pichler, Philippe Giron, Oleg Timofeev, Maxim Noeparast   +14 more
wiley   +1 more source

Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer

BMC Cancer, 2011
Background Patients with advanced or metastatic non-small cell lung cancer (NSCLC) can develop acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib.
Sun Jin, Zhang Zhiyuan, Wang Tongshan, Chen Xiaofen, Guo Renhua, Shu Yongqian   +5 more
doaj   +1 more source

Hippo Pathway–YAP/TAZ Signaling: Molecular Mechanisms, Biological Function, Diseases, and Therapeutic Targets

MedComm, Volume 7, Issue 10, October 2026.
The Hippo–YAP/TAZ–TEAD pathway integrates mechanical and biochemical cues to govern organ growth, regeneration, cancer, and fibrosis. This review dissects pathway physiology, TEAD structural pharmacology and ligandable pockets, and therapeutic strategies spanning palmitoylation‐pocket inhibitors, PROTAC degraders, and gene/RNA therapies, highlighting ...
Xiaodan Qu, Zhan‐you Wang
wiley   +1 more source

LINC00665 Induces Acquired Resistance to Gefitinib through Recruiting EZH2 and Activating PI3K/AKT Pathway in NSCLC

Molecular Therapy: Nucleic Acids, 2019
Gefitinib, a tyrosine kinase inhibitor of epidermal growth factor receptor, has been used as the first choice of treatment for advanced non-small-cell lung cancer.
Xinyin Liu, Xiyi Lu, Fuxi Zhen, Shidai Jin, Tongfu Yu, Quan Zhu, Wei Wang, Kun Xu, Jiaqi Yao, Renhua Guo   +9 more
doaj   +1 more source

Glutamine Metabolism in Health and Diseases

MedComm, Volume 7, Issue 10, October 2026.
Glutamine metabolism acts as a metabolic hub connecting cellular stress adaptation, immune regulation, and disease development. Through regulating energy production, biosynthesis, redox balance, and nitrogen metabolism, glutamine supports cellular homeostasis under physiological and pathological conditions.
Yi Ding, Fan Tong, Jing Zeng, Chun‐Ping Cui   +3 more
wiley   +1 more source

Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance

, 2015
Xiwei Yu,1,* Guang Yang,2,* Yijie Shi,1 Chang Su,3 Ming Liu,1 Bo Feng,1 Liang Zhao1 1School of Pharmacy, Liaoning Medical University, Jinzhou, People’s Republic of China; 2Department of Oncology, BenQ Medical Center, Nanjing Medical University ...
Yang G, Shi YJ, Su C, Zhao L, Liu M, Yu XW, Feng B   +6 more
core